Casper Steenholdt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9047455/publications.pdf

Version: 2024-02-01

		304743	214800
62	2,220	22	47
papers	citations	h-index	g-index

65	65	65	2315
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Localised colonic AL amyloidosis: a rare manifestation of a rare disease. Frontline Gastroenterology, 2023, 14, 171-172.	1.8	0
2	Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 559-568.e5.	4.4	14
3	A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patientsâ€™ and physiciansâ€™ preferences and adherence. Scandinavian Journal of Gastroenterology, 2022, 57, 274-281.	1.5	4
4	P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice. Journal of Crohn's and Colitis, 2022, 16, i441-i441.	1.3	0
5	Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. Stem Cells, 2022, 40, 447-457.	3.2	6
6	Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics. Scandinavian Journal of Gastroenterology, 2022, , 1-7.	1.5	4
7	Discontinuation of Infliximab Therapy in Patients with Crohnâ€™s Disease. , 2022, 1, .		17
8	Colonic actinomycosis mimicking malignant stenosing tumors. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
9	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 2456.	4.4	0
10	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterology Journal, 2021, 9, 91-101.	3.8	14
11	Severe ulcerative oesophagitis caused by primary Epstein-Barr virus infection in an immunocompetent individual. BMJ Open Gastroenterology, 2021, 8, e000586.	2.7	2
12	P381 Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S394-S395.	1.3	0
13	P599 Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study. Journal of Crohn's and Colitis, 2021, 15, S545-S546.	1.3	0
14	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
15	Drug Levels Associated with Optimal Discrimination Between Remission and Non-Remission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	2.0	1
16	Herpes Zoster Meningoencephalitis: A Novel, Rare, Potentially Fatal Side Effect to Tofacitinib. American Journal of Gastroenterology, 2021, Publish Ahead of Print, 195-196.	0.4	1
17	Postoperative complications and waiting time for surgical intervention after radiologically guided drainage of intra-abdominal abscess in patients with Crohnâ€™s disease. BJS Open, 2021, 5, .	1.7	11
18	Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 884-890.	1.5	11

#	Article	IF	Citations
19	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine, 2020, 20, 100271.	7.1	23
20	Tu1006 â€“ Development of an Evidence-Based Strategy Incorporating Patient Reported Outcomes and Physiciansâ€™ Preferences to Monitor Biological Therapies in Inflammatory Bowel Disease. Gastroenterology, 2019, 156, S-943-S-944.	1.3	1
21	Methotrexate for inflammatory bowel disease: time for reconsideration. Expert Review of Gastroenterology and Hepatology, 2019, 13, 407-409.	3.0	6
22	P377 Clinical strategies based on patient-reported outcomes and physiciansâ€™ preferences to monitor biological therapy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S294-S294.	1.3	0
23	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. Therapeutic Drug Monitoring, 2019, 41, 235-242.	2.0	4
24	A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 298-305.	1.3	23
25	Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 1583-1591.	2.3	8
26	Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive. Clinical Gastroenterology and Hepatology, 2018, 16, 597-598.	4.4	4
27	Outcome of continued infliximab therapy in Crohnâ€™s disease patients with response but without remission after one year of infliximab â€“ a retrospective cohort study. Scandinavian Journal of Gastroenterology, 2018, 53, 930-937.	1.5	3
28	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterology, 2018, 5, e000208.	2.7	29
29	Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1210-1217.	1.9	21
30	Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?. Alimentary Pharmacology and Therapeutics, 2017, 45, 759-760.	3.7	2
31	Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohnâ€™s Disease Is Determined by Their Concentration. AAPS Journal, 2017, 19, 223-233.	4.4	25
32	P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2017, 11, S409-S409.	1.3	0
33	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Medicine, 2017, 15, 184.	5.5	34
34	Monitoring immunogenicity of protein-based TNF antagonists. Frontline Gastroenterology, 2016, 7, 152-154.	1.8	2
35	Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2016, 50, 483-489.	2.2	18
36	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory Bowel Diseases, 2016, 22, 1999-2015.	1.9	82

#	Article	IF	Citations
37	Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-Î± Independent Crohn Disease. Medicine (United States), 2016, 95, e3417.	1.0	19
38	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2016, 55, 257-274.	3.5	42
39	Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies. Danish Medical Journal, 2016, 63, .	0.5	5
40	Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2015, 9, 1032-1042.	1.3	16
41	Transient and Persistent Antibodies Against TNF-Inhibitors in IBD. American Journal of Gastroenterology, 2015, 110, 1623-1624.	0.4	8
42	Authorsâ€™ response: Importance of defining loss of response before therapeutic drug monitoring. Gut, 2015, 64, 1340-1341.	12.1	6
43	Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 238-245.	1.3	56
44	Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohnâ€™s Disease Patients Failing Infliximab. Digestive Diseases and Sciences, 2015, 60, 2762-2770.	2.3	73
45	Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFÎ± Therapy. American Journal of Gastroenterology, 2015, 110, 1526-1532.	0.4	20
46	Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open, 2014, 4, e005887.	1.9	11
47	Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD. Inflammatory Bowel Diseases, 2014, 20, 1714-1721.	1.9	90
48	Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial. American Journal of Gastroenterology, 2014, 109, 1055-1064.	0.4	125
49	Individualised therapy is more cost-effective than dose intensification in patients with Crohnâ€™s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut, 2014, 63, 919-927.	12.1	413
50	Preâ€existing IgG antibodies crossâ€reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 1172-1183.	3.7	43
51	Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. Therapeutic Drug Monitoring, 2013, 35, 530-538.	2.0	104
52	Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. Danish Medical Journal, 2013, 60, B4616.	0.5	16
53	Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 650-659.	3.7	45
54	Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 108-111.	1.3	62

#	Article	IF	Citations
55	Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. Journal of Crohn's and Colitis, 2012, 6, 358-361.	1.3	26
56	Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scandinavian Journal of Gastroenterology, 2012, 47, 518-527.	1.5	89
57	Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2209-2217.	1.9	90
58	Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scandinavian Journal of Gastroenterology, 2011, 46, 310-318.	1.5	171
59	Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 51-58.	3.7	135
60	Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2011, 34, 404-405.	3.7	5
61	Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scandinavian Journal of Gastroenterology, 2009, 44, 774-781.	1.5	134
62	Expression and function of toll-like receptor 8 and Tollip in colonic epithelial cells from patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2009, 44, 195-204.	1.5	46